Clive Morris

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

Alex A. Adjei, Roger B. Cohen, Wilbur A. Franklin et al. · Journal of Clinical Oncology · 2008 · 573 citations · Full text

Medicine, Oncology, Pharmacology +17

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Udai Banerji, D. Ross Camidge, Henk M.W. Verheul et al. · Clinical Cancer Research · 2010 · 210 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +13

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

John D. Hainsworth, C. Cebotaru, Vladimir Kanarev et al. · Journal of Thoracic Oncology · 2010 · 160 citations · Full text

Medicine, Oncology, Pharmacology +11

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Jaafar Bennouna, István Láng, Manuel Valladares‐Ayerbes et al. · Investigational New Drugs · 2010 · 139 citations · Full text

Medicine, Oncology, Pharmacology +9

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer

Nicolas Guibert, Greg Jones, John F. Beeler et al. · Lung Cancer · 2019 · 105 citations · Full text

Medicine, Molecular Biology, Oncology +15